Nicole DeFeudis

The FDA has once again re­ject­ed HLB and Jiang­su Hen­grui Phar­ma­ceu­ti­cals’ drug com­bi­na­tion to treat the most com­mon form of liv­er can­cer. Ko­re­an biotech HLB

Sign up for free to read a limited number of articles each month. Pick what newsletters get delivered to your inbox each week. Biopharma ENDPOINTS

The Trump ad­min­is­tra­tion de­fend­ed HHS’ re­jec­tion of drug­mak­ers’ 340B re­bate mod­els “at this time,” but sug­gest­ed that the agency could be open to fur­ther con­sid­er­a­tion

Mehmet Oz has com­mit­ted to de­fend­ing Medicare drug price ne­go­ti­a­tions in court if he is con­firmed to lead CMS. The nom­i­nee sailed through a rough­ly

Tre­vi Ther­a­peu­tics’ chron­ic cough drug re­duced pa­tients’ 24-hour cough fre­quen­cy by 57% com­pared to place­bo in a Phase 2a tri­al, ex­ceed­ing in­vestors’ ex­pec­ta­tions. The com­pa­ny